NCT02303769

Study to Investigate the Efficacy and Safety of GL2702 GLARS-NF1tablet and Harnal-D - Tablet in BPH Patients With LUTS

A Multicenter, Randomized, Double -Blind, Parallel, Comparative, Phase III Study to Investigate the Efficacy and Safety of GL2702 GLARS-NF1 Tablet in BPH Patients With LUTS

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 309 (actual)
• Sponsor: GL Pharm Tech Corporation · Industry
• Sex: Male
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

Study to investigate the efficacy and safety of GL2702 GLARS-NF1tablet and Harnal-D - tablet in benign prostatic hyperplasia patients with lower urinary tract symptomatic

Detailed description

GL2702 GLARS-NF1 tablet is controlled released formation which is made by GL Pharm Tech

Conditions

• Benign Prostatic Hyperplasia

Interventions

Type	Name	Description
DRUG	Tamsulosin HCL 0.4mg	Tamsulosin HCL 0.4mg once a day
DRUG	Tamsulosin HCL 0.2mg	Tamsulosin HCL 0.2mg once a day

Timeline

• Start date: 2014-03-01
• Primary completion: 2015-05-01
• Completion: 2015-10-01
• First posted: 2014-12-01
• Last updated: 2016-02-25

Locations

1 site across 1 country: South Korea